Yoong W, Shah P, Dadswell R, Green L
Incontinence Unit, North Middlesex University Hospital, London, UK.
Int Urogynecol J. 2013 May;24(5):795-9. doi: 10.1007/s00192-012-1936-3. Epub 2012 Sep 7.
The aim of the study was to describe effectiveness and safety of percutaneous tibial nerve stimulation (PTNS) at 2 years in women with overactive bladder (OAB) syndrome unresponsive to pharmacotherapy.
Of 30 women who had initial positive response to PTNS, 23 continued to receive maintenance treatment and were reassessed at 2 years using bladder symptom diaries and the Incontinence Impact Questionnaire (IIQ-7). They were also questioned on acceptability and any adverse effects of long-term peripheral neuromodulative treatment.
Data from 23 women were available and 7 had been lost to follow-up. With maintenance treatment, the median nocturnal frequency at 2 years had decreased by 57 % (3.5 to 1.5 times/night), while the median IIQ-7 had reduced from 30.4 to 21.5 (both p<0.01) compared to pre-treatment baseline. Median nocturnal frequency and IIQ-7 scores at 2 years were comparable to those documented after initial response to treatment at 6 weeks, suggesting that maintenance therapy continued to suppress OAB symptoms. Daytime frequency and daily urgency incontinence episodes at 2 years were statistically similar to those documented at 6 weeks and remained lower than pre-treatment baseline (6.5 vs 11.8 and 2.0 vs 3.5, respectively, p<0.05). The women received a median of 8.42 treatments per year and the median length between treatments was 64.3 days. Apart from hypaesthesia in the toe of one responder lasting for 4 months, there were no reported side effects.
Women receiving PTNS for intractable OAB syndrome reported significant symptom relief at 2 years. This remains a safe mode of second-line treatment with excellent durability.
本研究旨在描述经皮胫神经刺激(PTNS)对药物治疗无反应的膀胱过度活动症(OAB)综合征女性患者2年时的有效性和安全性。
30名对PTNS初始反应为阳性的女性中,23名继续接受维持治疗,并在2年时使用膀胱症状日记和尿失禁影响问卷(IIQ-7)进行重新评估。还询问了她们对长期外周神经调节治疗的可接受性和任何不良反应。
获得了23名女性的数据,7名失访。通过维持治疗,2年时夜间排尿频率中位数下降了57%(从每晚3.5次降至1.5次),而IIQ-7中位数从30.4降至21.5(均p<0.01),与治疗前基线相比。2年时夜间排尿频率中位数和IIQ-7评分与6周时初始治疗反应后的记录相当,表明维持治疗继续抑制OAB症状。2年时白天排尿频率和每日急迫性尿失禁发作次数与6周时记录的统计结果相似,且仍低于治疗前基线(分别为6.5次对11.8次和2.0次对3.5次,p<0.05)。这些女性每年接受的治疗中位数为8.42次,治疗间隔的中位数为64.3天。除了一名反应者脚趾感觉减退持续4个月外,未报告有副作用。
接受PTNS治疗顽固性OAB综合征的女性在2年时报告症状明显缓解。这仍然是一种安全的二线治疗方式,具有出色的持久性。